Long-Term Value Through Scientific Excellence

Investors & Share Price Information

Bachem offers strong growth potential as a leader in peptides and oligonucleotides, backed by innovation, scalability, and a long‑term commitment to value creation.

Hero_subpage_img
Pattern
Pattern

Stock market information

Track Bachem’s performance in real time with our live, interactive stock graph.

Upcoming financial events

Corporate Governance

Bachem’s corporate governance is grounded in clarity, responsibility, and a commitment to ethical behavior. Our shareholder‑elected Board of Directors sets the strategic direction of the company and provides guidance for long‑term value creation. The Corporate Executive Committee ensures this strategy is translated into action by managing global operations and driving excellence across all functions. At the foundation of our culture stands the Bachem Code of Conduct, which defines how we act every day - ensuring integrity, compliance, and responsible decision‑making throughout the organization.

image_text_img
Pattern Pattern

Sign up for our financial news

 
 

Analyst Coverage

As a stock listed company, Bachem is as a company reviewed and commented upon by analysts on a regular basis. According to our best knowledge, the hereunder mentioned finance institutions prepare and issue Bachem related reports. There is no guarantee regarding the completeness and correctness of the list, although we strive to maintain and update it. Bachem does not comment on any analyst report and disclaims any liability in relation with statements or recommendations made therein as well as transactions based thereon.

Baader Helvea AG
Wiechert Konstantin
table_mail_icons kwiechert@helvea.com table_phone_icons +41 43 388 9213
Barclays
Charles Pitman-King

CFA | European Pharmaceuticals

table_mail_icons charles.pitman-king@barclays.com table_phone_icons +44 (0) 20 3134 6023
Berenberg Bank
Estelle Bétrisey
table_mail_icons estelle.betrisey@berenberg.com table_phone_icons +41 44 283 20 23
Deutsche Bank
Fynn Scherzler
table_mail_icons fynn.scherzler@db.com table_phone_icons +49 (69) 910-40764
Jefferies
Christopher Richardson
table_mail_icons chris.richardson@jefferies.com table_phone_icons +44 20 70298675
J.P. Morgan
Zain Ebrahim

VP EMEA Equity Research European Pharma & Biotech

table_mail_icons zain.ebrahim@jpmorgan.com table_phone_icons +44 203 493 1163
Octavian AG
Laura Pfeifer-rRossi
table_mail_icons laura.pfeifer-rossi@octavian.ch table_phone_icons +41 44 520 06 29
Research Partners AG
Dr. Martin Vögtli
table_mail_icons martin.voegtli@researchpartners.ch table_phone_icons +41 44 533 40 30
Royal Bank of Canada Europe Ltd
Charles Weston, CFA

Director, European Healthcare Equity Research

table_mail_icons charles.weston@rbccm.com table_phone_icons +44 20 7429 8425
UBS
Tanya Hansalik
table_mail_icons tanya.hansalik@ubs.com table_phone_icons +41 44 238 20 53
Vontobel
Sibylle Bischofberger

Senior Analyst Equity Research

table_mail_icons sibylle.bischofberger@vontobel.com table_phone_icons +41 58 283 70 21
Zürcher Kantonalbank
Daniel Jelovcan

Senior Equity Analyst Medical Technology & CDMO Research

table_mail_icons daniel.jelovcan@zkb.ch table_phone_icons +41 44 292 35 25
ODDO BHF Asset Management
Stephan Wulf
table_mail_icons stephan.wulf@oddo-bhf.com table_phone_icons +49 69 718 2636

Your investor relations contact

Barbora Blaha

Head of Investor Relations

investor.relations@bachem.com